Metraipolis › archive › dc_7a29d1aa3ced

Therapeutic positioning of asciminib in chronic myeloid leukemia patients previously treated with multiple tyrosine kinase inhibitors in Qatar — Europe PMC PMID:41129058

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41129058
DOI
10.1007/s12672-[numero omesso]-7
License (as archived)
solo-consultazione
Archived
2026-11-09T02:33:03.701Z
SHA-256 of the archived text
4bc4583a58b0990b7595d4be3b30daab3e7945139a9a00c32ad982a2810d26b5
Stable URL of this page
https://metraipolis.com/documento/dc_7a29d1aa3ced

How to cite

Therapeutic positioning of asciminib in chronic myeloid leukemia patients previously treated with multiple tyrosine kinase inhibitors in Qatar — Europe PMC PMID:41129058 — Europe PMC (en), https://europepmc.org/article/MED/41129058 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_7a29d1aa3ced (Metraipolis archive dc_7a29d1aa3ced, sha256 4bc4583a58b0990b7595d4be3b30daab3e7945139a9a00c32ad982a2810d26b5)
BibTeX
@misc{dc7a29d1aa3ced,
  title = {Therapeutic positioning of asciminib in chronic myeloid leukemia patients previously treated with multiple tyrosine kinase inhibitors in Qatar — Europe PMC PMID:41129058},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41129058},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_7a29d1aa3ced; sha256 4bc4583a58b0990b7595d4be3b30daab3e7945139a9a00c32ad982a2810d26b5},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41129058. Agents can read the archived copy with the MCP tool read_document.